abrdn Life Sciences Investors
HQL
44 hedge funds and large institutions have $47.7M invested in abrdn Life Sciences Investors in 2013 Q4 according to their latest regulatory filings, with 9 funds opening new positions, 19 increasing their positions, 8 reducing their positions, and 4 closing their positions.
138% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 8
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
13% more funds holding
Funds holding: 39 → 44 (+5)
4% more capital invested
Capital invested by funds: $46.1M → $47.7M (+$1.63M)
0.4% less ownership
Funds ownership: 16.27% → 15.87% (-0.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$694K |
| 2 |
SG Americas Securities
New York
|
+$563K |
| 3 |
SFS
Shaker Financial Services
Arlington,
Virginia
|
+$563K |
| 4 |
JP Morgan Chase
New York
|
+$514K |
| 5 |
NEPWA
New England Private Wealth Advisors
Wellesley,
Massachusetts
|
+$326K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAM
Advisors Asset Management
Monument,
Colorado
|
-$5.74M |
| 2 |
WAM
Wolverine Asset Management
Chicago,
Illinois
|
-$483K |
| 3 |
NPC
National Planning Corporation
El Segundo,
California
|
-$386K |
| 4 |
BA
Bard Associates
Chicago,
Illinois
|
-$66.1K |
| 5 |
LPL Financial
San Diego,
California
|
-$52.7K |
HQL Hedge Fund Activity: Q4 2013 in Review
44 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in abrdn Life Sciences Investors (HQL) for Q4 2013, worth a combined $47.7M — up 3.5% from $46.1M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new HQL positions and 4 closed out — a net gain of 5 holders — while 19 added to existing stakes and 8 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $694K. The largest seller was Advisors Asset Management, cutting an estimated $5.74M.
- 44 institutional investors held abrdn Life Sciences Investors (HQL) as of Q4 2013, up from 39 in Q3 2013.
- Funds reported $47.7M of abrdn Life Sciences Investors stock for Q4 2013, up 3.5% quarter-over-quarter.
- 9 funds opened new abrdn Life Sciences Investors positions in Q4 2013 and 4 closed out, a net change of +5 holders.
- The largest abrdn Life Sciences Investors buyer in Q4 2013 was Morgan Stanley, an estimated $694K added.
- The largest abrdn Life Sciences Investors seller in Q4 2013 was Advisors Asset Management, an estimated $5.74M sold.
Based on aggregated 13F filings for Q4 2013.